Dalpiciclib
- Generic Name
- Dalpiciclib
- Drug Type
- Small Molecule
- Chemical Formula
- C25H30N6O2
- CAS Number
- 1637781-04-4
- Unique Ingredient Identifier
- 5ZHA5P4PFX
Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors
- First Posted Date
- 2024-02-06
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Fengzhi Feng
- Target Recruit Count
- 30
- Registration Number
- NCT06243185
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas
Phase 1
Recruiting
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT06225921
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Risen (Suzhou) Pharma Tech Co., Ltd.
- Target Recruit Count
- 306
- Registration Number
- NCT06208410
- Locations
- 🇨🇳
Henan Provincial Cancer Hospital, Zhengzhou, Henan, China
Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer
Phase 1
Recruiting
- Conditions
- Unresectable or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Target Recruit Count
- 146
- Registration Number
- NCT06167694
- Locations
- 🇨🇳
Chinese PLA General Hospital Fifth Medical Center, Beijing, Beijing, China
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 82
- Registration Number
- NCT06149130
- Locations
- 🇨🇳
Tongji Hospital Affiliated of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas
Phase 1
Recruiting
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT06109207
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）
Phase 2
Recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Hebei Medical University Fourth Hospital
- Target Recruit Count
- 144
- Registration Number
- NCT06107673
- Locations
- 🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
Phase 1
Not yet recruiting
- Conditions
- High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 660
- Registration Number
- NCT06099990
Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy
Phase 2
Not yet recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Shuangyue Liu
- Target Recruit Count
- 178
- Registration Number
- NCT05979220
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic Sarcoma
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT05952128
- Locations
- 🇨🇳
Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath